Program
ROS1/NTRK Inhibitor ANS03
Its studies are led by Avistone Biotechnology.
Furthest: phase 1, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Dec 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Avistone Biotechnology | 11 open or running | phase 1since Nov 29, 2024 | Nov 29, 2024 | Dec 30, 2027phase 1 · NCT06716138 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationFirst studyNCT06716138 · 96 planned · United States, China
Ahead
- Dec 30, 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationNCT06716138
TargetBeta
ROS1 →read by rule
“An orally bioavailable type II inhibitor of the receptor tyrosine kinase c-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinases (NTRKs), ”NCIt, by rule
Other programs on ROS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| taletrectinibrule | Nuvation Bio | phase 3 | 11 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| Fudotinibrule | guangzhou-joyo-pharma-co-ltd | phase 3 | 3 |
| Cross-over to JYP0322rule | guangzhou-joyo-pharma-co-ltd | phase 3 | 1 |
| Radiosensitizer VS-101rule | vspharmtech-co-ltd | phase 2 | 2 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration · United States, China | 1 | Recruiting | Dec 30, 2027 | 96 |
How it is read
Names in the registry
- “ANS03”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.